2BBBullish & Bearish
Latigo Biotherapeutics, Inc. (LTGO) trades on NASDAQ. It operates in the Health Care sector, Biotechnology industry. Its current 2BB score is 52 out of 100.
Latigo Biotherapeutics (Nasdaq: LTGO) is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction, with the goal to provide effective, rapid-acting pain relief.
Latigo Biotherapeutics, Inc.’s current 2BB score is 52 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|---|---|
| Activity | 59 | Moderate |
| Momentum | 50 | Stable |
| Financial strength | 43 | Normal |
| Risk | 36 | Low (provisional) |
| Founded | 2018 |
| Employees | 66 |
| 52-week range | $13.85 – $25.90 |
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|---|---|---|---|
| 2026-11-05 | -0.55 | -0.629 | $0.00 | $0.00 |
| 2026-09-03 | -27.59 | -0.5661 | $0.00 | $0.00 |